The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...
Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback